. 2017 May 4;16:188. doi: 10.1186/s12936-017-1832-x

Table 1.

Key characteristics of Study 1 and Study 2

	Study 1	Study 2
Countries	Benin, Burkina Faso, Gabon, Tanzania	Burkina Faso, Gabon, Kenya
N (planned)	210	180
N (pursued)	123	20
Age cohorts (years)	Adults (18–65)	Teenager (12–17)
	Children (7–17)	Children (2–11)^a
	Young children (0.5–6)^a
Parasitemia at inclusion	Adults: >100 parasites/µL	>2000 parasites/µL
Parasitemia at inclusion	Children: >1000 parasites/µL	>2000 parasites/µL
Severe malaria	Planned for young children cohort	No
SAR97276A treatment	1 day intramuscular 0.18 mg/kg (max. 12.5 mg)	3 days intramuscular once daily 0.5 mg/kg (max. 36 mg)
	3 days intramuscular 0.18 mg/kg (max. 12.5 mg)	3 days intramuscular once daily 0.5 mg/kg (max. 36 mg)
	1 day intravenous 0.14 mg/kg (max. 10 mg)	3 days intramuscular twice daily 0.25 mg/kg per dose (max. 18 mg per dose)
Control treatment	None	Artemether–lumefantrine

^aThese groups were not enrolled when study was conducted